Patents Assigned to Cancer Biologics of America, Inc.
  • Method for potentiating primary drugs in treating multidrug resistant disease
    Patent number: 6962927
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 8, 2005
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Method for potentiating primary drugs in treating multidrug resistant disease
    Patent number: 6911454
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: June 28, 2005
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Method for potentiating primary drugs in treating multidrug resistant disease
    Patent number: 6124315
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein "pumps" associated with such cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 26, 2000
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
    Patent number: 5332747
    Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, representing various parasitic diseases, apparently by reversing the glycoprotein "pumps" associated with such cells.
    Type: Grant
    Filed: June 13, 1990
    Date of Patent: July 26, 1994
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke
  • Use of tetrandrine and its derivatives to treat malaria
    Patent number: 5025020
    Abstract: The specification discloses the treatment of malaria through the use of tetrandrine and its derivatives.
    Type: Grant
    Filed: September 28, 1989
    Date of Patent: June 18, 1991
    Assignee: Cancer Biologics of America, Inc.
    Inventor: Knox Van Dyke